3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
1
Interventions
Rituximab
227
Cyclophosphamide
142
fludarabine
69
Vincristine
66
Methotrexate
62
Doxorubicin
54
fludarabine phosphate
53
Lenalidomide
49
Etoposide
49
Cytarabine
48
Prednisone
47
Dexamethasone
44
Filgrastim
43
Bortezomib
38
Whole-Body Irradiation
34
Gemcitabine
34
Melphalan
32
Radiotherapy
30
ibrutinib
29
Granulocyte Colony-Stimulating Factor
29
Alemtuzumab
29
obinutuzumab
28
Tacrolimus
28
Mycophenolic Acid
28
Antilymphocyte Serum
28
venetoclax
27
Calcium Dobesilate
27
Busulfan
27
Bendamustine Hydrochloride
27
idelalisib
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Tolbutamide
×
Lymphoid
×
Clear all
NCT01185548
2018-10-19
JZAR
Eli Lilly and Company
Phase 1
Terminated
4 enrolled
8 charts